• Forum
  • Aktiemarkeder
    • MarkederRealtidskurser, indekser og markedsudvikling
    • BørskalenderKommende resultater, noteringer og virksomhedsbegivenheder
    • UdbyttekalenderKommende og tidligere udbytter
  • Selskaber
    • SelskaberGennemse og filtrer den fulde liste over børsnoterede selskaber
    • OpdagInspiration til din næste investering
    • BørsnoteringerNye noteringer og kommende børsintroduktioner
    • Invitationer til generalforsamlingerDatoer for generalforsamlinger og aktionærinformation
  • Aktieanalyse
    • ResearchEkspertaktieanalyse og anbefalinger
    • ArtiklerNyheder, indsigter og markedskommentarer
    • inderesTVVideocenter for aktieanalyse, forskning og ekspertkommentarer
    • TransskriptionerFuldstændige udskrifter af resultatopkald og investormøder
    • AktieoversigtSammenlign nøgletal og udvikling på tværs af flere aktier
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.

Hamlet BioPharma

7,60 SEK+2,43 %10.7, 17.29
Mindre end 1K følgere

HAMLET B

Spotlight Stock Market

Biotechnology & Pharmaceuticals

Health Care

Oversigt
Finansielt overblik og estimater
Ejerskab
Dividend
Investorkonsensus
Sammenligne
+2,43 %
+4,97 %
-13,54 %
+38,69 %
+28,81 %
+80,31 %
+134,38 %
+4,62 %
+243,51 %

Hamlet BioPharma operates in the pharmaceutical industry. The company conducts drug development based on a tumor-killing protein-lipid complex, formed from two natural and harmless molecules found in breast milk. The development aims to produce preparations that will primarily be used for the treatment and prevention of cancer diseases. Hamlet BioPharma was founded in 2015 and is headquartered in Lund.

Læs mere
Markedsværdi
1,41 mia. SEK
Aktieomsætning
858,68 t SEK
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender
Alle
Selskabsmeddelelser
ViserAlle indholdstyper

Finanskalender
28.8
2026

Årsrapport '26

13.11
2026

Delårsrapport Q1'27

20.11
2026

Generalforsamling '26

Selskabsmeddelelse29.06.2026, 14.07

Hamlet BioPharma AB (publ): Hamlet BioPharma Receives European Regulatory Approval for Phase III Study of Alpha1H in Bladder Cancer

Hamlet BioPharma
Pressemeddelelse29.06.2026, 10.35

Hamlet BioPharma AB (publ): Briefglance Highlights Hamlet BioPharma's Collaboration with the University of Iowa and the Potential for Advanced Bladder Cancer Therapy

Hamlet BioPharma
Pressemeddelelse25.06.2026, 16.00

Hamlet BioPharma AB (publ): Hamlet BioPharma secures drug manufacturing at Phase III quality and release of Alpha1H for distribution to clinical trial sites

Hamlet BioPharma

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Opret konto
Pressemeddelelse23.06.2026, 12.00

Hamlet BioPharma AB (publ): Hamlet BioPharma's monthly digital investors' meeting on June 30th

Hamlet BioPharma
Pressemeddelelse22.06.2026, 17.30

Hamlet BioPharma AB (publ): Clinical trial expansion in the US, in collaboration with the University of Iowa, to treat high-risk, resistant, non-muscle-invasive bladder cancer (NMIBC)

Hamlet BioPharma
Pressemeddelelse17.06.2026, 11.45

Hamlet BioPharma AB (publ): Pre-initiation visit in Prague, for the Phase III trial of Alpha1H in bladder cancer

Hamlet BioPharma
Pressemeddelelse10.06.2026, 14.30

Hamlet BioPharma AB (publ): Continued success for the new anti-infective therapies developed by Hamlet BioPharma

Hamlet BioPharma
Selskabsmeddelelse22.05.2026, 09.00

Hamlet BioPharma AB (publ): Q3 INTERIMREPORTJANUARY-MARCH 2026

Hamlet BioPharma
Pressemeddelelse21.05.2026, 11.15

Hamlet BioPharma AB (publ): Monthly investor meeting on the 22nd of May when Hamlet BioPharma is releasing it's Q3 report

Hamlet BioPharma
Pressemeddelelse18.05.2026, 15.15

Hamlet BioPharma AB (publ): Hamlet Biopharma Secures New Patents and Allowances, Going from Strength to Strength in Innovation and Technology

Hamlet BioPharma
Pressemeddelelse23.04.2026, 15.15

Hamlet BioPharma AB (publ): Monthly investor meeting on the 29th of April

Hamlet BioPharma
Pressemeddelelse30.03.2026, 10.00

Hamlet BioPharma AB (publ): Hamlet BioPharma presented at the Financial Stockholm event on March 26, 2026

Hamlet BioPharma
Pressemeddelelse17.03.2026, 10.00

Hamlet BioPharma AB (publ): Hamlet BioPharmas digital monthly investor meeting on the 18th of March

Hamlet BioPharma
Selskabsmeddelelse06.03.2026, 18.31

Hamlet BioPharma AB (publ): Hamlet BioPharma signed a Letter of Intent to outline terms of a potential collaboration and a commercial agreement concerning Alpha 1H.

Hamlet BioPharma
Selskabsmeddelelse13.02.2026, 09.00

Hamlet BioPharma AB (publ): Q2 INTERIM REPORT OCT - DEC 2025

Hamlet BioPharma
Pressemeddelelse12.02.2026, 17.03

Hamlet BioPharma AB (publ): Nature Microbiology publishes the paper `'Targeted innate immune inhibition therapy compared with antibiotics for recurrent acute cystitis: a randomized, open-label phase 2 trial.''

Hamlet BioPharma
Pressemeddelelse11.02.2026, 10.30

Hamlet BioPharma AB (publ): Monthly investor meeting on the 13th of February when Hamlet BioPharma is releasing it's Q2 report

Hamlet BioPharma
Pressemeddelelse03.02.2026, 10.15

Hamlet BioPharma AB (publ): Collaboration agreement between Hamlet BioPharma and Immunoforge in South Korea

Hamlet BioPharma
Pressemeddelelse27.01.2026, 12.00

Hamlet BioPharma AB (publ): 𝗦𝘆𝗺𝗽𝗼𝘀𝗶𝘂𝗺 𝗼𝗻 𝗡𝗼𝘃𝗲𝗹 𝗧𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁𝘀 𝗳𝗼𝗿 𝗜𝗻𝗳𝗲𝗰𝘁𝗶𝗼𝗻𝘀 𝗮𝗻𝗱 𝗖𝗮𝗻𝗰𝗲𝗿

Hamlet BioPharma
Pressemeddelelse16.01.2026, 14.00

Hamlet BioPharma AB (publ): Invitation to digital meeting focusing on novel strategies for treating bacterial infections without antibiotics

Hamlet BioPharma